The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases

被引:43
|
作者
Hu, Changfeng [1 ]
Lu, Lu [2 ]
Wan, Jie-Ping [3 ]
Wen, Chengping [1 ]
机构
[1] Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Affiliated Hosp 3, Hangzhou 310053, Zhejiang, Peoples R China
[3] Jiangxi Normal Univ, Coll Chem & Chem Engn, Nanchang 330022, Jiangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Immunomodulatory activity; hydroxychloroquine; systemic lupus erythematosus; rheumatoid arthritis; rheumatic disease; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTIMALARIAL TREATMENT; RISK-FACTORS; PHASE-I; CHLOROQUINE; ARTHRITIS; METHOTREXATE; INHIBITION; EFFICACY; DRUGS;
D O I
10.2174/0929867324666170316115938
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hydroxychloroquine (HCQ) is known as one of the most fascinating synthetic antimalarial drugs during the last 50 years. It is currently among the most commonly employed medicines for the clinical treatment of rheumatic diseases, especially systemic lupus erythematosus and rheumatoid arthritis. In related mechanism studies, it has been found that HCQ possesses various immunomodulatory and anti-inflammatory activities. In addition, the effects of HCQ on anti-platelet, metabolic pathways, and antineoplasticity have also been disclosed in more recent studies. These significant findings on HCQ suggest the potential therapeutic applications of HCQ for treatment of many diseases, such as cancers, skin disease, antiphospholipid syndrome, etc. This review focuses on recent in vitro and clinical trials on its pharmacological mechanisms, therapeutic activities, and potential adverse effects.
引用
收藏
页码:2241 / 2249
页数:9
相关论文
共 50 条
  • [41] Mechanisms of hypertension in autoimmune rheumatic diseases
    Taylor, Erin B.
    Wolf, Victoria L.
    Dent, Elena
    Ryan, Michael J.
    BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (12) : 1897 - 1913
  • [42] Pain Mechanisms in Patients with Rheumatic Diseases
    Minhas, Deeba
    Clauw, Daniel Joseph
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2021, 47 (02) : 133 - 148
  • [43] Neuroendocrine mechanisms in rheumatic diseases - Preface
    Masi, AT
    Bijlsma, JWJ
    Chikanza, IC
    Cutolo, M
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (04) : XIII - XV
  • [44] DICLOFENAC SODIUM - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN RHEUMATIC DISEASES AND PAIN OF VARYING ORIGIN
    BROGDEN, RN
    HEEL, RC
    PAKES, GE
    SPEIGHT, TM
    AVERY, GS
    DRUGS, 1980, 20 (01) : 24 - 48
  • [45] Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases
    Watanabe, Ryu
    Hashimoto, Motomu
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (12)
  • [46] PHARMACOLOGICAL BASIS OF THE THERAPEUTIC EFFECT OF (-)DEPRENYL IN AGE-RELATED NEUROLOGICAL DISEASES
    KNOLL, J
    MEDICINAL RESEARCH REVIEWS, 1992, 12 (05) : 505 - 524
  • [47] PRINCIPLES OF NON-PHARMACOLOGICAL MANAGEMENT OF RHEUMATIC DISEASES
    Vlieland, T. Vliet
    Knittle, Keegan
    Adams, Jo
    Ndosi, Mwidmi
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 46 - 46
  • [48] Eriodictyol: a review of its pharmacological activities and molecular mechanisms related to ischemic stroke
    Guo, Sa
    Xing, Nan
    Xiang, Gelin
    Zhang, Yi
    Wang, Shaohui
    FOOD & FUNCTION, 2023, 14 (04) : 1851 - 1868
  • [49] The Pharmacological Rationales and Molecular Mechanisms of Ganoderma lucidum Polysaccharides for the Therapeutic Applications of Multiple Diseases
    Luo, Hua
    Tan, Dechao
    Peng, Bo
    Zhang, Siyuan
    Vong, Chi Teng
    Yang, Zizhao
    Wang, Yitao
    Lin, Zhibin
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2022, 50 (01): : 53 - 90
  • [50] Therapeutic potential and pharmacological activities of β-eudesmol
    Acharya, Bishwanath
    Chaijaroenkul, Wanna
    Na-Bangchang, Kesara
    CHEMICAL BIOLOGY & DRUG DESIGN, 2021, 97 (04) : 984 - 996